TPST has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TPST has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Tempest Therapeutics's preferred dividends for the three months ended in Jun. 2024 was $0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil.
The historical data trend for Tempest Therapeutics's Preferred Dividends can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tempest Therapeutics Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Preferred Dividends | - | - | - | - |
Tempest Therapeutics Quarterly Data | |||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Preferred Dividends | Get a 7-Day Free Trial | - | - | - | - | - |
A dividend that is accrued and paid on a company's preferred shares.
Tempest Therapeutics (NAS:TPST) Preferred Dividends Explanation
In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.
Preferred Dividends for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Justin Trojanowski | officer: Corporate Controller | C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080 |
Nicholas Maestas | officer: VP of Strategy and Finance | 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 20005 |
Versant Venture Capital Vi, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Versant Side Fund Iv, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Versant Venture Capital Iv, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Versant Ventures Iv, Llc | 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Thomas Woiwode | director, 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Versant Ventures Vi Gp-gp, Llc | 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Versant Ventures Vi Gp, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Versant Vantage Ii, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Versant Vantage Ii Gp-gp, Llc | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Versant Vantage Ii Gp, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Thomas W. Dubensky | director, officer: President | C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710 |
Samuel Whiting | officer: Chief Medical Officer | C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080 |
Rock Springs Capital Llc | 10 percent owner | 650 SOUTH EXETER STREET, SUITE 1070, BALTIMORE MD 21202 |
From GuruFocus
By Value_Insider Value_Insider • 11-22-2022
By Marketwired • 10-11-2023
By Marketwired • 08-10-2023
By Marketwired • 10-10-2023
By Value_Insider Value_Insider • 11-10-2022
By sperokesalga sperokesalga • 04-17-2023
By GuruFocusNews GuruFocusNews • 07-05-2022
By sperokesalga sperokesalga • 03-22-2023
By PurpleRose PurpleRose • 07-12-2022
By GuruFocusNews GuruFocusNews • 07-02-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.